Amarin Corp Plc (AMRN)

[HDGabor]

i-

I'm tracking it now for an opportunity to get back in.

If I was you, I would not do that ... but not my business

On June 8, 2022, Evofem Biosciences, Inc. (the “Company”) received a notice from the Nasdaq Hearings Panel (the “Panel”) that the Company would be permitted to continue its listing on The Nasdaq Capital Market through August 22, 2022 (the “Extended Date”) in order to afford the Company the opportunity to regain compliance with Nasdaq Continued Listing Rule 5550(a)(2) (the “Bid Price Rule”), which requires the Company’s listed securities to maintain a minimum bid price of $1.00 per share. On June 10, 2022, the Company received a notice from the Panel modifying the terms of the Panel’s June 8, 2022 notice.

As modified, the Panel’s decision is subject to certain conditions, including on or before (i) June 22, 2022, the Company must file a preliminary proxy statement to obtain shareholder approval for a reverse stock split (the “Reverse Split”), (ii) July 5, 2022, the Company must file a definitive proxy statement to obtain shareholder approval for the Reverse Split, (iii) August 3, 2022, the Company must hold a special meeting of the shareholders to obtain approval for the Reverse Split, (iv) August 9, 2022 (the “Effective Date”), the Company must effect the Reverse Split at a ratio sufficient to ensure compliance with the Bid Price Rule, and (v) August 22, 2022, the Company must have demonstrated compliance with the Bid Price Rule for a minimum of ten consecutive trading days.

Best,
G